参考文献/References:
[1] Liang P, Zu J, Yin J, et al. The independent impact ofnewborn hepatitis B vaccination on reducing HBVprevalence in China,1992-2006: A mathematical modelanalysis[J]. Journal of Theoretical Biology, 2015, 386(4):115-121.[2] Kim G A, Lim Y S, Han S, et al. High risk of hepatocellularcarcinoma and death in patients with immune-tolerant-phase chronic hepatitis B[J]. Gut, 2017, 67(5): 945-952.[3] Milich D R.The concept of immune tolerance in chronichepatitis B virus infection is alive and well[J].Gastroenterology, 2016, 151(5): 801-804.[4] 高红艳，刘娜，卢荣增，等. 慢性乙型肝炎免疫耐受期临床特征的研究[J]. 肝脏，2017(2): 170-172.[5] 吴凤萍，党双锁. 慢性 HBV 感染免疫耐受研究进展[J].临床肝胆病杂志，2017，33(5): 949-953.[6] 王贵强，王福生，成军，等. 慢性乙型肝炎防治指南(2015年版)[J]. 中华实验和临床感染病杂志(电子版)，2015，9(5): 6-25.[7] 刘玉明，李珂娴，沈先荣. 中医药对神经-内分泌-免疫网络的调节作用[J]. 解放军预防医学杂志，2017，35(1): 76-78.[8] 徐雪芹. 滋水涵木法治疗慢性乙型肝炎临床疗效的系统评价研究[J]. 中医临床研究，2015(16): 87-88.[9] 聂红明，梅昭荷，高月求，等. 补肾颗粒对慢性乙型肝炎患者 CD4+T 淋巴细胞整体免疫调控网络的影响[J].上海中医药大学学报，2016，30(2): 18-22.[10] 唐开斌，夏仁兴. 补肾解毒方与健脾解毒方对慢性乙肝患者不同阶段的 T 淋巴细胞功能影响的研究[J]. 世界中医药，2015(8): 1190-1193.[11] 曾庆磊，李春霞，徐光华，等. HBeAg 阳性慢性 HBV 感染者免疫耐受期和免疫清除期的误判[J]. 中华临床感染病杂志，2016，9(1): 59-61.[12] 蒋开平. 运用“春夏养阳 秋冬养阴”理论干预治疗慢性HBV 感染免疫耐受的探讨[J]. 中国中医药现代远程教育，2011(1): 7-9.[13] Bertoletti, A. The immune response during hepatitis B virusinfection[J]. Journal of General Virology, 2006, 87(6):1439-1449.[14] Li M , Zhou Z H , Sun X H , et al. Hepatitis B core antigenupregulates B7-H1 on dendritic cells by activating theAKT/ERK/P38 pathway: a possible mechanism of hepatitisB virus persistence[C]// Lab Invest, 2016: 1156-1164.[15] Said E A , Al-Reesi I , Al-Riyami M , et al. Increased CD86but Not CD80 and PD-L1 expression on liver CD68+ cellsduring chronic HBV infection[J]. PLOS ONE, 2016, 11(6):e0158265.[16] Tavakoli S, Mederacke I, Herzoghauff S, et al. Peripheralblood dendritic cells are phenotypically and functionallyintact in chronic hepatitis B virus (HBV) infection[J].Clinical and Experimental Immunology, 2010, 151(1):61-70.[17] Wu J, Meng Z, Jiang M, et al. Hepatitis B Virus SuppressesToll-like Receptor-Mediated Innate Immune Responses inMurine Parenchymal and Nonparenchymal Liver Cells[J].Hepatology, 2010, 49(4): 1132-1140.[18] Greyer M, Whitney P, Stock A, et al. T Cell Help AmplifiesInnate Signals in CD8+ DCs for Optimal CD8+ T CellPriming[J]. Cell Reports, 2016, 14(3): 586-597.[19] Montfoort N V, Aa E V D, Bosch A V D, et al. Hepatitis Bsurface antigen activates myeloid dendritic cells via asoluble CD14-dependent mechanism[J]. Journal ofVirology, 2016, 90(14): 6187-6199.[20] Wang H, Feng F, Wang X P, et al. Dendritic cells pulsed withHsp70 and HBxAg induce specific antitumor immuneresponses in hepatitis B virusassociated hepatocellularcarcinoma[J]. Molecular Medicine Reports, 2016, 13(2):1077-1082.[21] 梅昭荷，聂红明，汪蓉，等. 从 Th1 /Th2、Treg /Th17 之间的平衡研究轻、中度慢性乙型肝炎患者 CD4+T 淋巴细胞的免疫失衡状态[J]. 肝脏，2017(6): 513-516.[22] Rossol S, Marinos G, Carucci P, et al. Interleukin-12induction of Th1 cytokines is important for viral clearancein chronic hepatitis B[J]. Journal of Clinical Investigation,1997, 99(12): 3025-3033.[23] 史继静，张纪元，王福生. HBV 感染的免疫发病机制及抗病毒治疗策略[J]. 中国病毒病杂志，2017，7(3)：5-10.[24] Moreno-Cubero E, Larrubia J R, et al. Specific CD8~+ Tcell response immunotherapy for hepatocellular carcinomaand viral hepatitis[J]. World Journal of Gastroenterology,2016, 22(28): 6469-6483.